Amyris completes $84.8 million IPO, no effect on other, less qualified, IPO hopefuls

October 12, 2010 | Analyst Insight

Last week, Amyris Biotechnologies raised $84.8 million in its initial public offering (IPO), below its target of $100 million. At week's end, the stock was trading at about $17 a...

Login to View This Research

Already a Lux Client?

Sign In

Not a Lux Client?

Talk to Lux Research now and learn the benefits of becoming a member.

Lux Research

  • Helps clients find new business opportunities from emerging technologies in the physical and life sciences
  • Offers ongoing technology and market intelligence, as well as market data and consulting services
  • Now serves over 250 clients on six continents – multinational corporations, investors, governments, and SMEs
  • Has a Global reach, with offices in Boston, New York, Amsterdam, Singapore, Shanghai, and Tokyo
  • Combines deep technical expertise with business analysis to support strategic decisions

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 (0) 20-3460840

For APAC (Singapore)
+65 6592-6978